OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Comparative Effectiveness Research is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Propensity score matching and inverse probability of treatment weighting to address confounding by indication in comparative effectiveness research of oral anticoagulants	86
Safety and effectiveness of ataluren: comparison of results from the STRIDE Registry and CINRG DMD Natural History Study	78
Efficacy classification of modern therapies in multiple sclerosis	58
Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis	44
The prevalence, characteristics and treatment of hemorrhoidal disease: results of an international web-based survey	40
Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy	38
Early mobilization in enhanced recovery after surgery pathways: current evidence and recent advancements	36
Organized structure of real-world evidence best practices: moving from fragmented recommendations to comprehensive guidance	31
Evidence-based public policy making for medicines across countries: findings and implications for the future	29
Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients	27
Clinical therapeutic efficacy of mesenchymal stem cells derived from adipose or bone marrow for knee osteoarthritis: a meta-analysis of randomized controlled trials	26
Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost–effectiveness analysis	24
COVID-19 complications in males and females: recent developments	20
Corticosteroid use in viral pneumonia: experience so far and the dexamethasone breakthrough in coronavirus disease-2019	18
The use of nonrandomized evidence to estimate treatment effects in health technology assessment	18
Patient-related barriers to some virtual healthcare services among cancer patients in the USA: a population-based study	18
What is a meta-epidemiological study? Analysis of published literature indicated heterogeneous study designs and definitions	15
Robot-assisted minimally invasive transforaminal lumbar interbody fusion versus open transforaminal lumbar interbody fusion: a retrospective matched-control analysis for clinical and quality-of-life o	15
Replication of randomized clinical trial results using real-world data: paving the way for effectiveness decisions	14
Web-based decision aids to support breast cancer screening decisions: systematic review and meta-analysis	14
Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus	14
What works when: mapping patient and stakeholder engagement methods along the ten-step continuum framework	14
The prevalence, disease characteristics and treatment of chronic venous disease: an international web-based survey	14
Thromboembolic and bleeding events with rivaroxaban in clinical practice in Spain: impact of inappropriate doses (the EMIR study)	13
Evaluating patients' satisfaction and preferences with a secondary prevention cardiovascular polypill: the Aurora Study	13

Economic analysis of the use of video laryngoscopy versus direct laryngoscopy in the surgical setting	12
Network meta-analysis of nivolumab plus ipilimumab in the second-line setting for advanced hepatocellular carcinoma	12
A prospective, randomized, controlled, crossover study comparing three multilayered foam dressings for the management of chronic wounds	12
Real-world evidence and nonrandomized data in health technology assessment: using existing methods to address unmeasured confounding?	12
The problem of underdosing with direct-acting oral anticoagulants in elderly patients with nonvalvular atrial fibrillation	12
How does risdiplam compare with other treatments for Types 1–3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison	12
Robotic-assisted total hip arthroplasty: an economic analysis	12
Cost–effectiveness of empagliflozin compared with liraglutide based on cardiovascular outcome trials in Type II diabetes	11
Vaginal laser therapy for gynecologic conditions: re-examining the controversy and where do we go from here	11
Unmeasured confounding in nonrandomized studies: quantitative bias analysis in health technology assessment	11
Cost–effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke	11
Digital technologies in cancer care: a review from the clinician's perspective	10
An investigation to choose the proper therapy technique in the management of autism spectrum disorder	10
Estimates of the value of life lost from COVID-19 in Ohio	10
Matching-adjusted indirect comparison of palbociclib versus ribociclib and abemaciclib in hormone receptor-positive/HER2-negative advanced breast cancer	10
Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data inROS1+ NSCLC	10
Factors influencing breast cancer awareness: a cross-sectional study in China	10
Propensity score matching versus coarsened exact matching in observational comparative effectiveness research	9
Micronized purified flavonoid fraction in the treatment of hemorrhoidal disease	9
Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma	9
Impact of socioeconomic status on presentation, treatment and outcomes of patients with pancreatic cancer	9
Impact of telehealth on health care resource utilization during the COVID-19 pandemic	9
Matching-adjusted indirect comparison: entrectinib versus crizotinib in ROS1 fusion-positive non-small cell lung cancer	9
Impact of the COVID-19 pandemic on healthcare resource utilization across selected disease areas in the USA	9
Advancing community-engaged research: increasing trustworthiness within community-academic partnerships	9
Real-world evidence on clinical outcomes in immune thrombocytopenia treated with thrombopoietin receptor agonists	8
The next generation of rare disease drug policy: ensuring both innovation and affordability	8
Potential policy reforms to strengthen the accelerated approval pathway	8
Effectiveness of clinical Pilates and home exercises in sagittal cervical disorientation: randomized controlled study	8
The cost–effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark	8
Patient and caregiver experiences at a specialized primary care center for autistic adults	8
Assessing direct costs of treating metastatic triple-negative breast cancer in the USA	8
Efficacy of immunotherapy with PD-1 inhibitor in colorectal cancer: a meta-analysis	7
Type I collagen matrix plus polyhexamethylene biguanide antimicrobial for the treatment of cutaneous wounds	7
Assessing risk of bias judgments for blinding of outcome assessors in Cochrane reviews	7
Estimating the health benefits of timely diagnosis and treatment of transthyretin amyloid cardiomyopathy	7
Real-world treatment, clinical outcomes and healthcare resource utilization among persons with hemophilia A by age	7
Venous stenting for patients with outflow obstruction and leg ulcers: cost–effectiveness and budget impact analyses	7
CAR-T therapy and historical trends in effectiveness and cost–effectiveness of oncology treatments	7
Using real-world evidence in healthcare from Western to Central and Eastern Europe: a review of existing barriers	7
Missing data methods for intensive care unit SOFA scores in electronic health records studies: results from a Monte Carlo simulation	7
Identifying patient decisions and related information needs during decision making related to total knee arthroplasty	7
Comparison of intravenous versus topical tranexamic acid in primary total hip arthroplasty: a systematic review and meta-analysis of ten randomized trials	7
Safety and effectiveness of intranasal esketamine for treatment-resistant depression: a real-world retrospective study	7
Healthcare use and costs among Medicare enrollees on pirfenidone versus nintedanib for idiopathic pulmonary fibrosis	7
US cost–effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma	7
A systematic review of discounting in national health economic evaluation guidelines: healthcare value implications	6
Analyzing the concept of spillover effects for expanded inclusion in health economics research	6
Health technology assessment (HTA) in England, France and Germany: what do matched drug pairs tell us about recommendations by national HTA agencies?	6
The terminology conflict on efficacy and effectiveness in healthcare	6

Advantages of robotic arm-assisted total hip arthroplasty: a 90-day episode-of-care clinical utility and cost analysis	6
Evaluating real-world COVID-19 vaccine effectiveness using a test-negative case–control design	6
Effects of 12-week Pilates training program on cardiac autonomic modulation: a randomized controlled clinical trial	6
Golimumab improves patient-reported outcomes in daily practice of inflammatory rheumatic diseases in Germany	6
Single-arm oncology trials and the nature of external controls arms	6
Palbociclib versus abemaciclib in HR+/HER2- advanced breast cancer: an indirect comparison of patient-reported end points	6
Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis	6
The effects of pregnancy on relapse rates, disability and peripartum outcomes in women with multiple sclerosis: a systematic review and meta-analysis	6
Meta-analysis of immunogenicity and safety of human rabies vaccination under Zagreb and Essen regimens	6
Real-world switch patterns and healthcare costs in biologic-naive psoriasis patients initiating apremilast or biologics	6
Protocol for Digital Real-world Evidence trial for Adults with insomnia treated via Mobile (DREAM): an open-label trial of a prescription digital therapeutic for treating patients with chronic insomni	6
Effect of clinical Pilates training on balance and postural control in patients with Parkinson’s disease: a randomized controlled trial	6
Use of ibuprofen for the closure of patent ductus arteriosus in preterm infants: a systematic review of meta-analyses	6
Are eSports more than just sitting? A study comparing energy expenditure	5
Do implantable loop recorders impact the survival of patients with recurrent unexplained syncope?	5
The efficacy of 3D printing-assisted surgery in treating distal radius fractures: systematic review and meta-analysis	5
A review of stakeholder recommendations for defining fit-for-purpose real-world evidence algorithms	5
Respiratory and nonrespiratory COVID-19 complications in patients with obesity: recent developments	5
Cost–effectiveness and cost-benefit analysis of oliceridine in the treatment of acute pain	5
Factors affecting treatment selection and overall survival for first-line EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer	5
Cost-per-remitter with esketamine nasal spray versus standard of care for treatment-resistant depression	5
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment	5
The cost–effectiveness, of pegcetacoplan compared with ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria, in a UK setting	5
Implementation of the Connect for Health pediatric weight management program: study protocol and baseline characteristics	5
The triple win – implementation science benefits patients, healthcare systems and industry alike	5
TELEmedicine as an intervention for sepsis in emergency departments: a multicenter, comparative effectiveness study (TELEvISED Study)	5
Intracardiac echocardiography use and outcomes after catheter ablation of ventricular tachycardia	5
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 8	5
An observational cohort study of pelvic floor photobiomodulation for treatment of chronic pelvic pain	5
Estimating the risk of thrombotic events in people with congenital hemophilia A using US claims data	5
Cornerstones of ‘fair’ drug coverage: appropriate cost sharing and utilization management policies for pharmaceuticals	5
No protocol and no liability: a call for COVID crisis guidelines that protect vulnerable populations	5
Comparative effectiveness of nivolumab versus standard of care for third-line patients with small-cell lung cancer	5
Approaches for the identification of chronic kidney disease in CPRD–HES-linked studies	5
Tisagenlecleucel versus historical standard therapies for pediatric relapsed/refractory acute lymphoblastic leukemia	5
Six ways to foster community-engaged research during times of societal crises	5
Meta-analyses of deflazacort versus prednisone/prednisolone in patients with nonsense mutation Duchenne muscular dystrophy	5
The societal impact of a biologic treatment of ankylosing spondylitis: a case study based on secukinumab	4
Efficacy and safety of PD-1/PD-L1 and CTLA-4 immune checkpoint inhibitors in colorectal cancer: a meta-analysis	4
Sex-based differences in the outcomes of patients with lung carcinoids	4
Gender, socioeconomic status and emergency department visits among cancer survivors in the USA: a population-based study	4
Minimally invasive surgery for low-grade spondylolisthesis: percutaneous endoscopic or oblique lumbar interbody fusion	4
Semaglutide treatment for obesity in teenagers: a plain language summary of the STEP TEENS research study	4
Application of quantitative bias analysis for unmeasured confounding in cost–effectiveness modelling	4
Is Medicaid expansion associated with increases in palliative treatments for metastatic cancer?	4
Comparative effectiveness of glasdegib versus venetoclax combined with low-dose cytarabine in acute myeloid leukemia	4
Nonindependence of patient data in the clinical practice research datalink: a case study in atrial fibrillation patients	4
Real-world direct healthcare costs of treating recurrent high-grade serous ovarian cancer with cytotoxic chemotherapy	4
Comparative effectiveness of weekly versus every-2-weeks cetuximab in metastatic colorectal cancer in a US-insured population	4
Comparative efficacy of dabrafenib + trametinib versus treatment options for metastatic melanoma in first-line settings	4
Safety and efficacy of GP40071 compared with originator insulin aspart (NovoRapid ^® Penfill ^® ) in Type 1 diabetes mellitus	4
Consumer willingness to pay for a hypothetical Chagas disease vaccine in Brazil: a cross-sectional study and the implications	4
Comparative effectiveness of trastuzumab emtansine versus lapatinib plus chemotherapy for HER2+ metastatic breast cancer	4
Engaging patients and stakeholders in preresearch: findings from the Pipeline to Proposal Awards Initiative	4
The economic cost of racial disparities in perioperative care	4
European cooperation in health technology assessment implementation: the perspective of Central and Eastern European countries	4
Meta-analysis of visual pretreatment for the prevention of emergence delirium in children undergoing ophthalmic surgery	4
Surfactant therapy for meconium aspiration syndrome in neonates: a systematic overview of systematic reviews and recent clinical trials	4
Strategies to improve the availability of medicines in primary health care in Brazil: findings and implications	4
Influence of pharmaceutical services organization on the availability of essential medicines in a public health system	4
Dacomitinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost–effectiveness analysis	4
High-concentration nonavian high-molecular weight hyaluronan injections and time-to-total knee replacement surgery	4
Optimizing electronic capture of patient-reported outcome measures in oncology clinical trials: lessons learned from a qualitative study	4
Social determinants of health affect unplanned readmissions following acute myocardial infarction	4
Cost–effectiveness analysis of empagliflozin compared with glimepiride in patients with Type 2 diabetes in China	4
Indirect treatment comparison of olaparib and talazoparib in germline BRCA-mutated HER2-negative metastatic breast cancer	4